Kristen Quigley
Chief Operating Officer bij MOLECULAR TEMPLATES, INC.
Profiel
Kristen Quigley is currently the Chief Operating Officer at Molecular Templates, Inc. She started this position in 2023.
Prior to her current role, she worked as the Executive Director-Clinical Operations at Threshold Pharmaceuticals, Inc. Ms. Quigley completed her undergraduate degree at Washington University in St. Louis.
Actieve functies van Kristen Quigley
| Bedrijven | Functie | Begin |
|---|---|---|
| MOLECULAR TEMPLATES, INC. | Chief Operating Officer | 02-08-2023 |
Eerdere bekende functies van Kristen Quigley
| Bedrijven | Functie | Einde |
|---|---|---|
Threshold Pharmaceuticals, Inc.
 Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Chief Operating Officer | - |
Opleiding van Kristen Quigley
| Washington University in St. Louis | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| MOLECULAR TEMPLATES, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
